Cat. No. 2697
Alternative Name: Galanin(1-13)-Gln14-bradykinin(2-9)amide
Biological ActivitySelective galanin GAL1 receptor agonist (Ki values are 0.23 and 5.71 nM for GAL1 and GAL2 receptors respectively). Enhances food consumption in rats following i.c.v. administration and reduces CAP-induced inflammatory pain.
(Modifications: Arg-22 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Jimenez-Andrade et al (2006) Activation of peripheral galanin receptors: differential effects on nociception. Pharmacol.Biochem.Behav. 85 273. PMID: 16996122.
Mazarati et al (2006) Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype-selective agonists and the role of G-protein-mediated signaling. J.Pharmacol.Exp.Ther. 318 700. PMID: 16699066.
Lundstrom et al (2005) A galanin receptor subtype 1 specific agonist. Int.J.Pept.Res.Ther. 11 17.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses M617 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: M617, supplier, Selective, GAL1, GalR1, agonists, Receptors, Galanin, Tocris Bioscience, Galanin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands